Skip to content
MARKETS / NASDAQ / BTMD
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · MID CAP

biote Corp. BTMD

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$192.2M
▼ 2.5% YoY
$27.0M
▲ 756.7% YoY
$30.2M
▼ 22.2% YoY
In brief

What this company does

biote Corp. provides Biote-certified practitioners with the components to establish, build, and implement programs to optimize hormone levels using personalized solutions for their patients, in a model similar to a franchise. The company also sells a Biote-branded line of dietary supplements, and generates revenues by charging Biote-partnered clinics fees associated with the Biote Method and from the sale of those supplements. As of December 31, 2025, over 9,200 providers in more than 5,300 clinics nationwide had completed the company's curriculum and clinical training program. The company operates as one operating segment. As of December 31, 2025, the company had 223 employees, across 11 departments. Biote's headquarters are located at 1875 W. Walnut Hill Ln #100, Irving, Texas. On May 26, 2022, following completion of a business combination among Haymaker Acquisition Corp. III, Haymaker Sponsor III LLC, BioTE Management, LLC and other parties, HYAC changed its name to biote Corp.

Written from the business description in biote Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.

Growth
USD 192.2M
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 192.2 · Net income 27.0
80M160M20212022202320242025
Compound annual growth
+5.2%
−27.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
16 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 18.5% · Net 16.4%
10%20%-10%-20%-30%20212022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
USD 4.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 30.2
20M-4M-8M20212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends 1.7 · Net buybacks 3.1
5M10MDividendsNet buybacks20212022202320242025

USD 1.7M in dividends and USD 3.1M in buybacks — 18% of the year's profit went back to shareholders.

Total assetsUSD 107.6M
EquityUSD -58.5M
CashUSD 24.1M
Gross debtUSD 102.0M
Net debtUSD 77.9M
Current ratio1.22×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.20.20.20.20.1
Operating income $B0.00.00.0−0.10.0
EBITDA $B0.00.00.0−0.10.0
Income tax $B0.00.00.00.00.0
Net income $B0.00.00.0−0.00.0
Free cash flow $B0.00.00.0−0.00.0
EPS, diluted $0.740.090.13−0.12·
Dividend / sh $·····
Payout %6150262−1330103
ROE %····269.4
Shares out B···0.06·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 19 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 71 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2021

Share this section

Download image